These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30089162)

  • 1. Quality of medicines: Deficiencies found by Brazilian Health Regulatory Agency (ANVISA) on good manufacturing practices international inspections.
    Geyer ARC; Sousa VD; Silveira D
    PLoS One; 2018; 13(8):e0202084. PubMed ID: 30089162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The requirements for manufacturing highly active or sensitising drugs comparing Good Manufacturing Practices.
    Petrelli F; Caraffa A; Scuri S; Grappasonni I; Magrini E; Cocchini A
    Acta Biomed; 2019 May; 90(2):288-299. PubMed ID: 31125009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study.
    Tauqeer F; Myhr K; Gopinathan U
    Health Policy Plan; 2019 Jul; 34(6):440-449. PubMed ID: 31302684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aid conditionalities, international Good Manufacturing Practice standards and local production rights: a case study of local production in Nepal.
    Brhlikova P; Harper I; Subedi M; Bhattarai S; Rawal N; Pollock AM
    Global Health; 2015 Jun; 11():25. PubMed ID: 26072308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Good manufacturing practice inspections conducted by Tanzania medicines and medical devices authority: a comparative study of two fiscal years from 2018 to 2020.
    Sangeda RZ; Ndabatinya CJ; Maganga MB; Nkiligi EA; Mwalwisi YH; Fimbo AM
    J Pharm Policy Pract; 2024; 17(1):2399722. PubMed ID: 39291054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Good Manufacturing Practice for Medicinal Products in Bulgaria: an Analysis of Regulatory Inspection Findings.
    Stoimenova AH; Kirilov BJ; Gueorguiev SR; Petkova-Gueorguieva ES; Ognianov SG
    Folia Med (Plovdiv); 2020 Mar; 62(1):165-171. PubMed ID: 32337904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recall of substandard medicines in Brazil during the period 2010-2018.
    Oliveira CLCG; Machado VF; de Freitas Tavares H; Ribeiro GLM; Arrais PSD
    BMC Health Serv Res; 2023 Mar; 23(1):238. PubMed ID: 36899376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Utility of Remote Inspections During the COVID-19 Health Emergency and in the Postpandemic Setting.
    Mofid S; Bolislis WR; Brading C; Hamilton N; Hardit C; Nagaoka M; Parain J; Zanta M; Kühler TC
    Clin Ther; 2021 Dec; 43(12):2046-2063. PubMed ID: 34740466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Campaign manufacturing of highly active or sensitizing drugs: a comparison between the GMPs of various Regulatory Agencies.
    Petrelli F; Scuri S; Grappasonni I; Nguyen CTT; Cocchini A; Magrini E; Caraffa A
    Clin Ter; 2020; 170(1):e66-e73. PubMed ID: 31850487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Baseline Analysis of Regulatory Review Timelines for ANVISA: 2013-2016.
    Patel P; Cerqueira DM; Santos GML; de Lima Soares R; Sousa VD; Liberti L; McAuslane N
    Ther Innov Regul Sci; 2020 Nov; 54(6):1428-1435. PubMed ID: 32519282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil?
    Mueller LL; Taketsuma Costa SM
    Expert Opin Ther Pat; 2014 Jan; 24(1):1-4. PubMed ID: 24206261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of regulatory requirements on medicine registration in African countries - perceptions and experiences of pharmaceutical companies in South Africa.
    Narsai K; Williams A; Mantel-Teeuwisse AK
    South Med Rev; 2012 Jul; 5(1):31-7. PubMed ID: 23093897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmaceutical product quality control and good manufacturing practices].
    Hiyama Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2010; (128):1-16. PubMed ID: 21381389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency.
    Sellers JW; Mihaescu CM; Ayalew K; Kronstein PD; Yu B; Ning YM; Rodriguez M; Williams L; Khin NA
    Ther Innov Regul Sci; 2022 Sep; 56(5):753-764. PubMed ID: 35610469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Main Reasons for Registration Application Refusal of Generic and Similar Pharmaceutical Drug Products by the Brazilian Health Regulatory Agency (ANVISA).
    do Carmo AC; Piras SS; Rocha NF; Gratieri T
    Biomed Res Int; 2017; 2017():7894937. PubMed ID: 28280742
    [No Abstract]   [Full Text] [Related]  

  • 16. Good manufacturing practice: the role of local manufacturers and competent authorities.
    Tomić S; Filipović Sučić A; Ilić Martinac A
    Arh Hig Rada Toksikol; 2010 Dec; 61(4):425-36. PubMed ID: 21183434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of Brazilian Requirements for Therapeutic Equivalence of Orally Inhaled and Nasal Drug Products.
    Silva MC; Costa HS; Valadares BN; Grecchi L; Nagao L; Santos GML
    AAPS PharmSciTech; 2019 Jun; 20(6):235. PubMed ID: 31236849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation.
    Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B
    Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.